Clinical Trials

Gastrointestinal Oncology UCSF

Thank you for your interest in GI clinical trials at UCSF.

Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial.

Please see the links below for current open trials at UC San Francisco.

Colorectal | Early Phase | Gastro Esophageal | Hepatocellular
Neuroendocrine | PancreaticOpening Soon | All Cancer Trials at UCSF

 

COLORECTAL

METASTATIC
 
CC# 12451: A phase III clinical trial evaluating TheraSphere® in patients with metastatic colorectal carcinoma to the liver who have failed first line chemotherapy (TS-102)
Contact: Curt Johanson (415)353-2310: curt.johanson.ucsf.edu
 
CC# 124522 (GSK# MEK116833): An Open-Label, Three-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the anti-EGFR Antibody Panitumumab in Combination in Subjects with BRAF-mutation V600E or V600K Positive Colorectal Cancer
Contact: Claire Greene (415)514-6258: Claire.Greene@ucsf.edu
 
CTSU-S1406: Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Contact: Daniela Rodriguez-Jaquez (415)353-9544: Daniela.Rodriguez-Jaquez@ucsf.edu
 

NEOADJUVANT RECTAL

Alliance N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
Contact: Ari Alfaro (415) 353-7284: AlfaroA@cc.ucsf.edu
 
ADJUVANT

CALGB 80702: Phase III Trial of 6 vs 12 Treatments of Adjuvant FOLFOX +Celecoxib/Placebo for Resected Stage III Colon Cancer
Contact: Ari Alfaro (415) 353-7284: AlfaroA@cc.ucsf.edu

 
 

EARLY PHASE

CC#13957: A Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination with Continuous Intravenous Doses of PRI-724, a CBP/B-Catenin Inhibitor, to Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy with FOLFIRINOX (or FOLFOX)
Contact: Madeleine Zaehringer (415) 514-6674 : Madeleine.Zaehringer@ucsf.edu

CC#14952: A Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors
Contact: Wesley Goodman-Levy (415-514-6363) Wesley.Godman-levy@ucsf.edu

CC#14951: A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Solid Tumors
Contact: Armand Harb (415) 353-7281: Armand.Harb@ucsf.edu

CC#14958: An Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Contact: Kerry Inokuchi (415) 353-9535: Kerry.Inokuchi@ucsf.edu
 
CC#14959A Phase 1B, Multi-center, Open-label, Dose Finding Sstudy Of CC-122 In Combination With Sorafenib In Subjects With Unresectable Hepatocellular Carcinoma
Contact: Kerry Inokuchi (415) 353-9535: Kerry.Inokuchi@ucsf.edu
 
CC#149511: A Phase 1, Open-Label, Dose-Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors
Contact: Jenna Zhang (415) 514-8867: Jenna.Zhang@ucsf.edu
 
CC#15956A Phase 1, Open-Label, Dose Finding Study Of CC-90002, A Monoclonal Antibody Directed Against CD47, In Subjects With Advanced Solid And Hematologic Cancers
Contact:  Wesley Goodman-Levy (415) 514-6363: Wesley.Goodman-Levy@ucsf.edu
 

GASTRO ESOPHAGEAL

There are no trials open at this time.

 

HEPATOCELLULAR

CC# 124511: Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Contact: Blake Rosenthal (415)514-5633: Blake.Rosenthal@ucsf.edu
 
CC# 13455: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Contact: Blake Rosenthal (415)514-5633; Blake.Rosenthal@ucsf.edu

CC# 11452: Randomized Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma who Have Had Disease Progression on Sorafenib or Are Not Eligible to Receive Sorafenib
Contact: McKinley Nickerson (415)514-6314: NickersonM@cc.ucsf.edu

CC# 14958: An Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Contact: Kerry Inokuchi (415) 353-9535: Kerry.Inokuchi@ucsf.edu

CC# 15452A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
Contact: Daniela Rodriguez-Jaquez (415) 353-9544: Daniela.Rodriguez-Jaquez@ucsf.edu

 

NEUROENDOCRINE TUMORS

 
CTSU-E2211: A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
Contact: Ari Alfaro (415) 353-7284: AlfaroA@cc.ucsf.edu
 

CC#14952: A Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors
Contact:  Wesley Goodman-Levy (415-514-6363); Wesley.Godman-levy@ucsf.edu

CC#149511: A Phase 1, Open-Label, Dose-Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors
Contact: Jenna Zhang (415) 514-8867: Jenna.Zhang@ucsf.edu
 

CARCINOID TUMORS

Alliance A021202: Prospective Randomized Phase II Trial of Pazopanib (NSC #737754, IND #75648) Versus Placebo in Patients with Progressive Carcinoid Tumors
Contact: Claire Greene (415)514-6258: GreeneC4@cc.ucsf.edu

CC#14952: A Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors
Contact:  Wesley Goodman-Levy (415-514-6363) Wesley.Godman-levy@ucsf.edu

 

PANCREATIC

CC#13957: A Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination with Continuous Intravenous Doses of PRI-724, a CBP/B-Catenin Inhibitor, to Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy with FOLFIRINOX (or FOLFOX)
Contact: Madeleine Zaehringer (415) 514-6674 : Madeleine.Zaehringer@ucsf.edu

CC#14451: A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 Compared to Chemotherapy or to CRS-207 Alone in Adults with Previously-Treated Metastatic Pancreatic Adenocarcinoma
Contact: McKinley Nickerson (415)514-6314: NickersonM@cc.ucsf.edu  

CC#14452: A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma
Contact: Daniela Rodriguez-Jaquez (415)353-9544: Daniela.Rodriguez-Jaquez@ucsf.edu  

CC#14455: A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination with Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) in the Treatment of Metastatic Pancreatic Cancer
Contact: Ari Alfaro (415) 353-7284: AlfaroA@cc.ucsf.edu

CC#144520 Pilot Study of Autologous T-cells Redirected to Mesothelin and CD19 with a Chimeric Antigen Receptor in Patients with Metastatic Pancreatic Cancer
Contact:  Daniela Rodriguez-Jaquez (415)353-9544: Daniela.Rodriguez-Jaquez@ucsf.edu

CC#15454 A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 with or without Nivolumab in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma
Contact:  McKinley Nickerson (415) 514-6314: NickersonM@cc.ucsf.edu

CC#15459 A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of MM-141 plus Nab-Paclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-Line Metastatic Pancreatic Cancer (CARRIE)
Contact:  Ari Alfaro (415)353-7284: AlfaroA@cc.ucsf.edu

 

**************************************************
 

**TO BE OPENED WITHIN 3 MONTHS**

CC#144515: Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma
Contact:  Daniela Rodriguez-Jaquez (415)353-9544: Daniela.Rodriguez-Jaquez@ucsf.edu

CC#144525 A Phase Ib/II Safety and Efficacy Trial of Ibrutinib Combined with Gemcitabine and    Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
Contact: Nina Santos (415)353-7740: Nina.Santos@ucsf.edu
 
CC#15458 Merck-3475, Protocol 059 A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric Cancer
Contact : Ari Alfaro (415) 353-7284: AlfaroA@cc.ucsf.edu

CC#154511: A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer
Contact: Nina Santos (415)353-7740: Nina.Santos@ucsf.edu

 

For information on Phase 1 clinical trials not listed in this newsletter please contact: Anne Reinert, NP (415) 415-353-9291: Anne.Reinert@ucsfmedctr.org